#ViiV Healthcare

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

ViiV Healthcare teams with stock photography provider Shutterstock to offer a stigma-busting gallery of images.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.

Virtually, of course. So take a look around.

4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

The single-tablet regimen is now approved for previously treated people with an undetectable viral load.

Nine findings from ViiV Healthcare’s Latinx Listening Initiative

Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.